Bronchogen

Ala-Glu-Asp-Leu, AEDL, "lung tetrapeptide"

Immune & bioregulators

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Synthetic tetrapeptide (4 amino acids: alanine-glutamate-aspartate-leucine) from the Khavinson "cytogen" family
Mechanism: Proposed to bind DNA in bronchial epithelial cells and alter expression of genes for proliferation, differentiation and mucin/antioxidant function; shown in culture and rodents by one group
Routes studied: Injection (rodents); oral capsules (marketed form in Russia); inhaled/intranasal proposed but not tested
Dose range reported: In vitro: ~20 ng/ml typical in the group's culture work. Rodent: microgram/kg range. Community-reported: 1–2 capsules/day for 10–30 days. No validated human dose
Half-life: Not characterised; expected to be minutes in plasma
Storage: Lyophilised: refrigerate, protect from light. Capsules: room temperature, dry
Regulatory status: Not approved as a medicine anywhere. Sold in Russia as a food supplement †

Doses are as reported in studies or by the community — never recommendations.

1What it is

Bronchogen is a four-amino-acid synthetic peptide from the Khavinson group, aimed at the bronchial epithelium — the cells lining the airways. Of the short Khavinson peptides it has one of the better-documented mechanistic papers in an English-language journal (Khavinson 2014, Lung), which is why it is more often cited than its siblings. It is a synthetic compound, not a natural hormone, and it is sold in Russia as a supplement rather than as a medicine.

The same caveat applies as to the whole family: essentially all evidence is from the originating group; independent replication is absent to our knowledge; no human trial exists.

2How it's thought to work

Cell entry and DNA binding. fluorescence-labelled AEDL was among the peptides shown to enter the nucleus of HeLa cells and to bind oligonucleotides (Fedoreyeva 2011). The group proposes sequence-preferential binding at promoter regions.

Bronchial epithelium gene expression. in human bronchial epithelial cell cultures the group reported changes in expression of genes and proteins associated with proliferation (Ki-67), differentiation, mucin production (MUC genes) and other airway functions, with a stronger effect in "aged" (late-passage) cultures (Khavinson 2014, Lung).

Molecular modelling. the group has published docking models of AEDL sitting in the DNA minor groove at particular sequences; these are computational.

Proposed protective effect in infection. the 2020 COVID-19 review hypothesised a role in protecting airway epithelium; no data (Khavinson 2020, Molecules).

Proposed: a tetrapeptide directed at bronchial tissue, reported to influence gene expression in cultured cells. No controlled human trials.Schematic — not to scale

3What the research shows

Bronchial epithelial cell gene expression and differentiation

The core paper reports that AEDL in culture altered expression of a set of bronchial epithelium markers in a tissue-specific way and promoted differentiation markers in late-passage cells (Khavinson 2014, Lung; Khavinson 2012, Bull Exp Biol Med). This is , from the originating group. [1][3]

Lung tissue in rodents

Reviews from the group describe improved airway epithelium structure and antioxidant status in aged or injured rodents after courses of Bronchogen. Primary reports are mostly Russian-language (Khavinson & Malinin 2005). [4]

COPD, asthma, chronic bronchitis in humans

No controlled trial. Russian-language uncontrolled observations exist for the family of products. Community reports are anecdotal and mixed. Thin literature; stated plainly.

4Reported side effects and interactions

Literature-reported

No adverse effects reported in the group's work; no peer-reviewed human safety data.

Community-reported

Very few reports; essentially none describe adverse effects, and many describe no perceived effect.

Theoretical. Promoting epithelial proliferation in airways is, in principle, a reason for caution in anyone with a history of lung cancer or pre-malignant airway changes; unmeasured.

Interactions. None established. No data with inhaled corticosteroids or bronchodilators.

Markers researchers commonly monitor

No compound-specific markers are established. Commonly discussed:

Marker	Why it's watched
Peak flow or spirometry (FEV1)	the only objective, repeatable measure of the claimed target organ that members can track.
Resting SpO2	cheap daily baseline.
hs-CRP	general inflammation.
CBC and CMP	general baseline for a compound with no human safety data.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Marketed in Russia as oral capsules; injectable vials (10–20 mg) also circulate. For vials, with , swirl gently, refrigerate, protect from light.

Open in calculator, pre-loaded →

6Commonly studied alongside

Chonluten (#82) — the group's usual respiratory pairing; Thymalin/Thymogen; Epitalon (#13). None studied in combination in humans.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Not FDA-approved; not a permitted supplement ingredient. Not on the 2023 Category 2 list to our knowledge †
European Union	Not authorised
United Kingdom	Not licensed
Australia	Not approved †
South Africa	Not registered
Sport (WADA)	Not specifically named; S0 as a non-approved substance †

8Open questions

Oral bioavailability and whether any AEDL reaches airway epithelium.
Independent replication of the Lung 2014 gene-expression findings.
Any human airway outcome measured under control.

9References

1Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. PubMed · DOI
2Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). PubMed · DOI
3Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. PubMed · DOI
4Khavinson VKh, Malinin VV (2005). Gerontological Aspects of Genome Peptide Regulation. Karger, Basel. DOI
5Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. PubMed · DOI
6Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide regulation of gene expression: a systematic review. Molecules. PubMed · DOI

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.